In breast cancer, the combination of CDK4/6i with endocrine therapy became standard procedure and is certainly essential to restrict adaptive events, via reduction of Cyclin D1 levels and Cyclin E1 activity (102). The gene discussed is CDK4; the disease is breast carcinoma.